Ultragenyx's second PRV sale; Biomea's oral GLP-1 data leads to stock slump

GLP-1Positive

AI Analysis

Summary

Ultragenyx Pharmaceutical sold its second priority review voucher this month for $203 million. Biomea's oral GLP-1 data announcement led to a stock decline.

Outcome Details

Ultragenyx sold second priority review voucher (PRV) for $203 million

Importance:4/10

Sentiment:

0.30

priority_review_voucherrare_diseaseglp1stock_movement

Related Companies

$RARE $SNY

Read the original article

Published by Endpoints News on October 14, 2026 2:24 PM

Read Original